The effect of an aerobic exercise bout 24 h prior to each doxorubicin treatment for breast cancer on markers of cardiotoxicity and treatment symptoms: a RCT
- 795 Downloads
In rodents, a single exercise bout performed 24 h prior to a single doxorubicin treatment provides cardio-protection. This study investigated whether performing this intervention prior to every doxorubicin treatment for breast cancer reduced subclinical cardiotoxicity and treatment symptoms.
Twenty-four women with early stage breast cancer were randomly assigned to perform a 30-min, vigorous-intensity treadmill bout 24 h prior to each of four doxorubicin-containing chemotherapy treatments or to usual care. Established echocardiographic and circulating biomarkers of subclinical cardiotoxicity, as well as blood pressure and body weight were measured before the first and 7–14 days after the last treatment. The Rotterdam symptom checklist was used to assess patient-reported symptoms.
The exercise and usual care groups did not differ in the doxorubicin-related change in longitudinal strain, twist, or cardiac troponin. However, the four total exercise bouts prevented changes in hemodynamics (increased cardiac output, resting heart rate, decreased systemic vascular resistance, p < 0.01) and reduced body weight gain, prevalence of depressed mood, sore muscles, and low back pain after the last treatment (p < 0.05) relative to the usual care group. No adverse events occurred.
An exercise bout performed 24 h prior to every doxorubicin treatment did not have an effect on markers of subclinical cardiotoxicity, but had a positive systemic effect on hemodynamics, musculoskeletal symptoms, mood, and body weight in women with breast cancer. A single exercise bout prior to chemotherapy treatments may be a simple clinical modality to reduce symptoms and weight gain among women with breast cancer.
KeywordsDoxorubicin Breast cancer Cardiotoxicity Exercise Treatment symptoms
This work was supported by an Anita Cochrane Memorial Fund Award from the British Columbia Cancer Foundation. AK was supported by the Canadian Institutes of Health Research. We also acknowledge the support of GE Healthcare.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
- 2.Plana JC, Galderisi M, Barac A et al (2014) Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 27:911–939. https://doi.org/10.1016/j.echo.2014.07.012 CrossRefPubMedGoogle Scholar
- 4.Thavendiranathan P, Poulin F, Lim K-D et al (2014) Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol 63:2751–2768. https://doi.org/10.1016/j.jacc.2014.01.073 CrossRefPubMedGoogle Scholar
- 6.Patnaik JL, Byers T, DiGuiseppi C et al (2011) Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res 13:R64. https://doi.org/10.1186/bcr2901 CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Godin G (2011) The godin-shephard leisure-time physical activity questionnaire. Health Fit J Can 4:18–22Google Scholar
- 15.Lang RM, Badano LP, Mor-Avi V et al (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 28(1–39):e14. https://doi.org/10.1016/j.echo.2014.10.003 Google Scholar
- 20.Sawaya H, Sebag IA, Plana JC et al (2012) Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 5:596–603. https://doi.org/10.1161/CIRCIMAGING.112.973321 CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Stoodley PW, Richards DAB, Boyd A et al (2013) Altered left ventricular longitudinal diastolic function correlates with reduced systolic function immediately after anthracycline chemotherapy. Eur Heart J Cardiovasc Imaging 14:228–234. https://doi.org/10.1093/ehjci/jes139 CrossRefPubMedGoogle Scholar
- 24.Lange SA, Jung J, Jaeck A et al (2015) Subclinical myocardial impairment occurred in septaland anterior LV wall segments after anthracycline-embedded chemotherapy and did not worsen during adjuvant trastuzumab treatment in breast cancer patients. Cardiovasc Toxicol. https://doi.org/10.1007/s12012-015-9328-9 Google Scholar
- 25.Tan TC, Bouras S, Sawaya H et al (2015) Time trends of left ventricular ejection fraction and myocardial deformation indices in a cohort of women with breast cancer treated with anthracyclines, taxanes and trastuzumab. J Am Soc Echocardiogr 28:509–514. https://doi.org/10.1016/j.echo.2015.02.001 CrossRefPubMedGoogle Scholar
- 30.Bosch X, Rovira M, Sitges M et al (2013) Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the overcome trial (prevention of left ventricular dysfunction with enalapril and carvedilol in patients submitted to intensive Chemotherapy for the treatment of malignant hemopathies). J Am Coll Cardiol 61:2355–2362CrossRefPubMedGoogle Scholar
- 31.Gulati G, Heck SL, Ree AH et al (2016) Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 37:1671–1680. https://doi.org/10.1093/eurheartj/ehw022 CrossRefPubMedPubMedCentralGoogle Scholar
- 36.Metivier F, Marchais SJ, Guerin AP et al (2000) Pathophysiology of anaemia: focus on the heart and blood vessels. Nephrol Dial Transplant 15:14–18. https://doi.org/10.1093/oxfordjournals.ndt.a027970 CrossRefPubMedGoogle Scholar